Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells

Diabetologia

Volumn 40, Issue 2, 1997, Pages 165-172

  Cominacini, L ^a,c   Garbin, U ^a   Pastorino, A M ^b   Campagnola, M ^a   Fratta Pasini, A ^a   Davoli, A ^a   Rigoni, A ^a   Lo Cascio, V ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b GLAXOSMITHKLINE   (United States)

^c Policlinico   (Italy)

Author keywords

Alpha tocopherol; Atherosclerosis; Cu++; Diabetes mellitus; Endothelial cells; LDL oxidation; Oxidized LDL; Troglitazone; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; COPPER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TROGLITAZONE;

ARTICLE; CELL CULTURE; ELECTROPHORESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPID PEROXIDATION; OXIDATION; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; CELLS, CULTURED; CHROMANS; COPPER; DIABETES MELLITUS; ENDOTHELIUM; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; THIAZOLES; THIAZOLIDINEDIONES; VITAMIN E;

EID: 0031029934     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050658     Document Type: Article

References (51)

1. Avogaro P, Bittolo Bon G, Cazzolato G (1988) Presence of a modified low density lipoprotein in humans. Arteriosclerosis 8: 79-87
2. Boyd HC, Gown AM, Wolfbauer G, Chait A (1989) Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 135: 815-824
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modification of low-density lipoprotein that increases its atherogenicity. New Engl J Med 320: 915-924
4. Rosenfeld ME (1991) Oxidized LDL affects multiple atherogenic cellular responses. Circulation 83: 2137-2140
5. Wiklund O, Mattson L, Bjornheden T, Camejo G, Bondjers G (1991) Uptake and degradation of low density lipoproteins in atherosclerotic rabbit aorta: role of local LDL modification. J Lipid Res 32: 55-62
6. Palinsky W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10: 325-332
7. Quinn M, Parthasarathy S, Fong LG, Steinberg D (1987) Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci 84: 2995-2998
8. Berliner JA, Territo MC, Sevanian A, et al. (1990) Minimally modified low-density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85: 1260-1266
9. Yla-Herttuala S, Palinsky W, Rosenfeld ME, et al. (1989) Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesion of rabbit and man. J Clin Invest 84: 1086-1098
10. Esterbauer H, Jurgens G, Quehenberger O, Koller E (1987) Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 28: 495-509
11. Cominacini L, Garbin U, Davoli A, et al. (1991) A simple test for predisposition to LDL oxidation based on the fluorescence development during copper-catalyzed oxidative modification. J Lipid Res 32: 349-358
12. Mao SJ, Yates MT, Rechtin AE, Jackson RI, Van Sickle WA (1991) Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J Med Chem 34: 298-302
13. Sasahara M, Raines EW, Chait A, et al. (1994) Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 94: 155-164
14. Lavy A, Brook GJ, Dankner G, Amotz AM, Aviram M (1991) Enhanced in vitro oxidation of plasma lipoprotein derived from hypercholesterolemic patients. Metabolism 40: 794-799
15. Cominacini L, Pastorino AM, Garbin U et al. (1994) The susceptibility of LDL to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition 10: 527-531
16. Regnstrom JN, Nilsson J, Tornavall P, Landou C, Hamsten A (1992) Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339: 1183-1186
17. Cominacini L, Garbin U, Pastorino AM, et al. (1993) Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 99: 63-70
18. Maggi E, Bellazzi R, Falaschi F, et al. (1994) Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 45: 876-883
19. Panzetta O, Cominacini L, Garbin U, et al. (1995) Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effect of fish oil and vitamin E administration. Clin Nephrol 44: 303-309
20. Maggi E, Marchesi E, Ravetta V, Falaschi F, Finardi G, Bellomo G (1993) Low-density lipoprotein oxidation in essential hypertension. J Hypertension 11: 1103-1111
21. Cominacini L, Garbin U, Pastorino AM, et al. (1994) Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 26: 173-184
22. Ciaraldi TP, Gilmore A, Olefsky JM (1990) In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39: 1056-1062
23. Fujiwara T, Yoshioca S, Yoshioca T (1988) Characterization of new oral antidiabetic agent CS-045. Diabetes 37: 1549-1555
24. Kuzuya T, Iwamoto Y, Kosaka K et al. (1991) A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 11: 147-153
25. Mimura K, Umeda F, Hiramatsu S et al. (1994) Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11: 685-691
26. Kumar S, Boulton AJM, Beck-Nielsen H et al. (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709
27. Yoshioca T, Fujita T, Kanai T (1989) Studies on hindred phenols and analogues. I. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32: 421-427
28. Steiner C (1985) Atherosclerosis, the major complication of diabetes. Adv Exp Med Biol 189: 277-297
29. Nagano Y, Nakamura T, Matsuzawa Y, Cho M, Ueda Y, Kita T (1992) Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Long term antiatherogenic effect and effects on established plaques. Atherosclerosis 96: 131-140
30. Havel RJ, Eder MA, Bragdon JM (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353
31. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. J Clin Invest 52: 2745-2752
32. Cominacini L, Garbin U, De Santis A, et al. (1995) Mechanisms involved in the in vitro modification of low density lipoprotein by human umbilical vein endothelial cells and copper ions. J Lipid Mediators Cell Signalling 13: 19-33
33. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC (1989) Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 83: 2008-2017
34. Landegren U (1984) Measurement of cell numbers by means of the endogenous enzyme hexosaminidase: application to detection of lymphokines and cell surface antigens. J Immunol Methods 67: 379-385
35. Lehmann J, Martin HL (1982) Improved direct determination of alpha-and gamma-tocopherol in plasma and platelets by liquid chromatography, with fluorescence detection. Clin Chem 28: 1345-1353
36. von Sonntag C, Schuchmann H (1994) Suppression of hydroxyl radical reaction in biological systems: consideration based on competition kinetics. Method Enzymol 233: 47-56
37. Smith PK, Krohn RI, Hermanson GT et al. (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 105: 293-299
38. Steel RGD, Torrie JH (1960) Principles and procedures of statistics. McGraw-Hill, New York
39. Dunnett CW (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50: 1096-1121
40. Cominacini L, Garbin U, Fratta Pasini A, Campagnola M, Young MMR, Capriati A (1996) Troglitazone increases the resistance of LDL to oxidation in healthy volunteers. Diabetologia 39 [Suppl 1]:A233 (Abstract)
41. Niki E (1987) Antioxidants in relation to lipid peroxidation. Chem Phys Lipids 44: 227-253
42. Cominacini L, Garbin U, Cenci B, et al. (1991) Predisposition to LDL oxidation during copper-catalyzed oxidative modification and its relation to alpha-tocopherol content in humans. Clin Chim Acta 204: 57-68
43. Princen HMG, Van Poppel G, Vogelezang C, Buytenhek R, Kok RFJ (1992) Supplementation with vitamin E but not beta carotene in vivo protects low density lipoproteins from lipid peroxidation in vitro. Arterioscler Thromb 12: 554-562
44. Esterbauer H, Gebicki J, Puhl H, Jurgens G (1992) The role of lipid peroxidation and antioxidants in oxidative modifications of LDL. Free Rad Biol Med 13: 341-390
45. Cathcart MA, McNally AK, Morel DW, Chisholm GM (1989) Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein to a cytotoxin. J Immunol 142: 1963-1969
46. Cathcart MK, McNally AK, Chisholm GM (1991) Lipoxygenase-mediated transformation of human low density lipoprotein to an oxidized cytotoxic complex. J Lipid Res 32: 63-70
47. Chamulitrat W, Hughes MF, Eling TE, Mason RP (1991) Superoxide and peroxyl radical generation from the reduction of polyunsaturated fatty acid hydroperoxides by soybean lipoxygenase. Arch Biochem Biophys 290: 153-159
48. Ezaki M, Witztum JL, Steinberg D (1995) Lipoperoxides in LDL incubated with fibroblasts that overexpress 15-lipoxygenase. J Lipid Res 36: 1996-2004
49. Thomas ST, Neuzil J, Mohr D, Stocker R (1995) Coantioxidants make a-tocopherol an efficient antioxidant for low a density lipoprotein. Am J Clin Nutr 62: 1357-1364
50. Nagasaka Y, Kaku K, Nakamura K, Kaneko T (1995) The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem Pharmacol 50: 1109-1111
51. Packer JA, Slater TF, Wilson RL (1979) Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 278: 738-741